Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9675591
Methods for treating seizure disorders and pain
granted -
US 9675544
Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
granted -
US 9675623
Non-surgical method of treatment for cataract
granted -
US 9675550
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
granted -
US 9675678
Compositions and methods for treatment of homocystinuria
granted -
US 9675615
2,3-dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections
granted -
US 9670506
Modified immunization vectors
granted -
US 9670251
ANG-(1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 9669016
Antiparasitic effect of Bis[3,5-Bis(Benzylidene)-4-Oxo-1-Piperidinyl]amide Derivatives
granted -
US 9673409
Phosphorescent tetradentate metal complexes having modified emission spectra
granted -
US 9670281
Binding-triggered transcriptional switches and methods of use thereof
granted -
US 9670254
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 9670244
Oxysterol compounds and the hedgehog pathway
granted -
US 9669098
Metal-organic frameworks with exceptionally large pore aperatures
granted -
US 9662488
Systems and methods for selectively migrating cells using electric fields
granted -
US 9663585
Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
granted -
US 9663564
Vectors and methods to treat ischemia
granted -
US 9662377
Therapeutic composition for treatment of glioblastoma
granted -
US 9662307
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
granted -
US 9662424
Hydrogel membrane for adhesion prevention
granted -
US 9663504
Salts of heterocyclic modulators of HIF activity for treatment of disease
granted -
US 9655909
Personalized medicine for the prediction of therapy targeting the hedgehog pathway
granted -
US 9657090
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
granted -
US 9656001
Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
granted -
US 9655938
Compositions of polymeric myrcene
granted -
US 9649340
Methods for producing enriched populations of human retinal pigment epithelium cells
granted -
US 9650607
Modalities for the treatment of degenerative diseases of the retina
granted -
US 9650447
Complement receptor 2 (CR2) targeting groups
granted -
US 9650407
Reprogramming of cellular adhesion
granted -
US 9649344
Methods and compositions for in vivo induction of pancreatic beta cell formation
granted -
US 9649358
Methods for use of neural stem cell compositions for treatment of central nervous system lesions
granted -
US 9649373
Neoseptins: small molecule adjuvants
granted -
US 9649321
Phosphonate compounds
granted -
US 9650436
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
granted -
US 9651562
Cathelicidin as novel inflammatory bowel disease marker and therapy for colitis associated intestinal fibrosis
granted -
US 9644238
Methods of isolating non-senescent cardiac stem cells and uses thereof
granted -
US 9642916
Porphyrin modified telodendrimers
granted -
US 9642859
Use of capsazepine and analogs thereof to treat cancer
granted -
US 9645139
Neuroprotective chemicals and methods for identifying and using same
granted -
US 9644039
Acid-degradable and bioerodible modified polyhydroxylated materials
granted -
US 9642843
Pharmaceutical compounds and use of same in cancer and tauopathies
granted -
US 9639665
Methods for diagnosis and intervention of hepatic disorders
granted -
US 9638639
Plasmonic-magnetic bifunctional nanotubes for biological applications
granted -
US 9637519
Peptide for inducing mast cell-specific apoptosis and use thereof
granted -
US 9636515
Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use
granted -
US 9637524
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
granted -
US 9631041
PH-sensitive compositions for delivery of beta lapachone and methods of use
granted -
US 9629877
Human application of engineered chimeric antigen receptor (CAR) T-cells
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory